

PTO/SB/08B (10-01)
Approved for parcugh 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office #U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B-PTO 10/016,977 **Application Number** December 12, 2001 INFORMATION DISCLOSURE First Named Inventor **Kin-Ping WONG** Art Snit JUN 2 4 2002 STATEMENT BY APPLICANT 1614 Not Yet Assigned Examiner Name (use as many sheets as necessary) Attorney Booksi Allember AN 2002.00 Sheet 2 of

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal,	T
Initials*	No.1	serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	<u> </u>
, ,	1	ACHEN, M.G. and STACKER, S.A. "The Vascular Endothelial Growth Factor Family; Proteins Which	
8nL		Guide the Development of the Vasculature" Int. J. Exp. Path. (1998) 79:255-265	
SOL	2	AUGUSTIN, H.G. et al. "Ovarian Angiogenesis Phenotypic Characterization of Endothelial Cells in a	
		Physiological Model of Blood Vessel Growth and Regression" Am. J. Pathol. (1995) 147(2):339-351	<u> </u>
me	3	BROOKS, P.C. et al. "Requirement of Vascular Integrin α <sub>ν</sub> β <sub>3</sub> for Angiogenesis" <i>Science</i> (1994)	
		264:569-571	
m	4	BROOKS, P.C. et al. "Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells	
		by Interaction with Integrin ανβ3" Cell (May, 1996) 85:683-693	-
m	5	BUSSOLINO, F., et al. "Molecular Mechanisms of Blood Vessel Formation" Trends in Biochem Sci	
110		(1997) <b>22</b> (7):251-256	-
m	6	CONNOLLY, D.T. et al. "Determination of the Number of Endothelial Cells in Culture Using an Acid	
-///		Phosphatase Assay" Anal. Biochem. (1986) 152:136-140	$\vdash$
Soft	7	DEVALARAJA, M. and RICHMOND, A. "Multiple Chemotactic Factors: Fine Control or Redundancy?"	
2		Trends in Pharmacol. Sci. (1999) 20(4):151-156	
M	8	FOLKMAN, J. "Angiogenesis in Cancer, Vasular, Rheumatoid and Other Diseases" <i>Nature Med.</i> (1995) <b>1(1)</b> :27-31	
76	9	FOLKMAN, J. and D'AMORE, P.A. "Blood Vessel Formation: What is its Molecular Basis?" Cell (1996)	
SOL	9	87:1153-1155	
	10	GOODGER, A.M. (MacPherson) and ROGERS, P.A.W. "Blood Vessel Growth in the Endometrium"	1
GN1	10	Microcirculation (1995) <b>2(4)</b> :329-343	l
in	11	HANAHAN, D. "Signaling Vascular Morphogenesis and Maintenance" Science (1997) 277:48-50	_
	12	HEALY, D.L. et al. "Angiogenesis: A New Theory for Endometriosis" Hum. Reprod. Update (1998)	
me	,-	<b>4(5)</b> :736-740	
	13	KOCH, A.E. et al. "Angiogenesis Mediated by Soluble Forms of E-Selectin and Vascular Cell Adhesion	
加		Molecule-1" Nature (1995) 376:517-519	
_	14	MAISONPIERRE, P.C. et al. "Angiopoietin-2, a Natural Antagonist for Tie2 that Disrupts in vivo	
m		Angiogenesis" Science (1997) 277:55-60	
	15	MIGNATTI, P. and RIFKIN, D.B. "Plasminogen Activators and Matrix Metalloproteinases in	
SME		Angiogenesis" Enzyme Protein (1996) 49:117-137	_
C- 1	16	NGUYEN, M. et al. "Quantitation oof Angiogenesis and Antiangiogenesis in the Chick Embryo	
M		Chorioallantoic Membrane" Microvas. Res. (1994) 47:31-40	
M	17	O'REILLY, M.S. et al. "Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of	
		Metastases by a Lewis Lung Carcinoma" Cell (1994) 79(2):315-328	
1001	18	O'REILLY, M.S. et al. "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth" Cell	
SM		(1997) 88(2):277-285	<u> </u>
ر م	19	PINTUCCI, G. et al. "Angiogenesis and the Fibrinolytic System" Semin Thromb Hemost (1996)	
m		22(6):517-524	_
90V	20_	POLVERINI, P.J. "The Pathophysiology of Angiogenesis" (Crit Rev Oral Biol Med (1995) 6(3):230-247	-
Sol_	21	RISAU, W. "Mechanisms of Angiogenesis" Nature (1997) 386:671-674	<u> </u>
Sonc	22	SATO, T.N. et al. "Distinct Roles of the Receptor Tyrosine Kinases Tie-1 and Tie-2 in Blood Vessel	l

Considered: Sum De lee 12/9/02

•		10/016,97	7			
		Sheet 2 of Attorney Docket Nober AN 2002.00				
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T²			
m	23	SURI, C. et al. "Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, During Embryonic ngiogeneisis" Cell (1996) 87:1171-1180				
m	24		697			
m	25	WALSH, D.A. "Angiogenesis and arthritis" Rheumatology (1999) 38(2):103-112	씽			
Sor	26		A STATE			
m	27	WILTING, J. and CHRIST, B. "Embroynic Angiogenesis: A Review" Naturwissenschaften (1996) 83:153-164				
		2				
		· C				
		The state of the s				
		Charles of the control of the contro				
		The state of the s				
		On a				
		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~				
	ļ					
<del></del>	ļ					
		·				
Examiner's		Date ( )				
Signature		Monny De Considered 12/9/02				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.